Trevi Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Trevi Therapeutics

18/03/2024 20:23

* Trevi Therapeutics Inc  TRVI.OQ   TRVI.O  is expected
to show no
change in quarterly revenue when it reports  results on March 20
for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Trevi Therapeutics Inc
is for
a loss of 9 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Trevi
Therapeutics Inc is $7.50​, above​ its last closing price
of $3.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.09       -0.09      -0.08     Beat    12.7
 Jun. 30 2023  -0.09       -0.08      -0.07     Beat    17.6
 Mar. 31 2023  -0.07       -0.07      -0.06     Beat    18.2​
 Dec. 31 2022  -0.12       -0.10      -0.06     Beat    42.9
 ​​Sep.        -0.13       -0.13      -0.12     Beat    11.1
 30 2022                                                
 Jun. 30 2022  -0.18       -0.18      -0.14     Beat    24​
 Mar. 31 2022  -0.29       -0.29      -0.24     Beat    16.3
 Dec. 31 2021              -0.30      -0.28     Beat    5.7
 This summary was machine generated March 18 at 20:23 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)